NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
We believe that signs of recovery in ad revenue segment will likely be visible in Q3 FY24E. We think listed companies (general entertainment channel) should report sequential increase in ad revenue despite higher market share taken by sports channels in the quarter.
We estimate ad revenues of Zee Entertainment Enterprises Ltd., Sun TV Ltd. and PVR Inox Ltd. to grow 3%, 6% and 19% sequentially.
We believe subscription revenue growth trend is likely to continue. However, in the broader media space, news flow around consolidation will be key to driving stock performance.
We believe that despite an underwhelming performance of the content pipe-line, PVR Inox will be able to better manage the fluctuations in the profitability given structural improvement in business model post-merger.
We believe this playing out could be a key argument for the PVR Inox to re-rate.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

PVR Inox Plans To Add 200 Screens In Two Years: ED Sanjeev Kumar Bijli


Inox Wind Gets 'Buy' Rating As Motilal Oswal Initiates Coverage


'Buy' Sun Pharma Shares Maintains Nirmal Bang, Says India, Specialty To Drive Growth


SPARC Confirms Pipeline Strength, No Capex Plans After Psoriasis Drug Setback — Profit Exclusive
